Carfilzomib is primarily metabolized via peptidase and epoxide hydrolase activities, and as a result, the pharmacokinetic profile of carfilzomib is unlikely to be affected by concomitant administration of cytochrome P450 inhibitors and inducers. Carfilzomib is not expected to influence exposure of other drugs [see Pharmacology: Pharmacokinetics under Actions].
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
